About KalVista


KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet need.

Our initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can lead to increased vascular permeability, edema and inflammation. We have developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

The strategy is to develop a portfolio of oral molecules and evaluate multiple candidates in the clinic to provide one or more potential best-in-class therapies for HAE and DME patients. As part of this strategy, we will select molecules whose properties can support multiple therapies for HAE patients, such as for prophylactic as well as acute treatment.



In HAE, we are advancing multiple drug candidates into Phase 1 clinical trials, with additional program candidates in preclinical development. Our most advanced candidate, KVD900, is in a Phase 2 clinical trial for on-demand treatment of HAE, with data from this trial expected in 2020. In DME, our most advanced compound, an intravitreally administered plasma kallikrein inhibitor known as KVD001, has completed a Phase 2 clinical trial in patients with DME. 

We have an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in disease, and a management team with the capability to bring small molecules through the clinic to commercialization.

Our offices and labs are in Cambridge, MA and Salisbury, UK.